HDI Publications by date
Using the Search: Choose a publication year, then use search to find papers within that year. No results? The paper may have been published in a different year — try selecting another year and searching again.
Change in the Use of Fractionation in Radiotherapy Used for Early Breast Cancer at the Start of the COVID-19 Pandemic
M.R. Gannon, D. Dodwell, K. Miller, K. Horgan, K. Clements, J. Medina, I. Kunkler, D.A. Cromwell
Aims
Adjuvant radiotherapy is recommended for most patients with early breast cancer (EBC) receiving …
Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England
Kearney M, Knott CS, Mahmoudpour H, Verpillat P.
Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England. ESMO 2022; 2022 Sept 9-13
Evolution of the treatment landscape in patients with advanced or metastatic cancers following the approval of immuno-oncology treatments
Mahmoudpour H, Knott CS, Amin A, Boutmy E, Verpillat P.
Evolution of the treatment landscape in patients with advanced or metastatic cancers following the approval of immuno-oncology treatments: analysis of the …
Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis
Heffernan K, Sen Nikitas FS, Shukla U, Camejo HS, Knott CS.
Abstract:
Objectives: In patients with recurrent/advanced endometrial cancer who have progressed after first-line treatment, there are a lack of …
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al.
Abstract:
Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction …
Comparison of survival outcomes between dostarlimab and comparator treatments (tx) in patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC) in England
Goulden S, Heffernan K, Nikitas FS, Shukla U, Knott CS, Hunger M, Pahwa A, Schade R.
Comparison of survival outcomes between dostarlimab and comparator treatments (tx) in patients (pts) with advanced/recurrent …
An overview on synthetic administrative data for research
Theodora Kokosi, Bianca De Stavola, Robin Mitra, Lora Frayling, Aiden Doherty, Iain Dove, Pam Sonnenberg, Katie Harron;
Abstract:
Use of administrative data for research and for planning services has increased …
Short-term mortality in ovarian, fallopian tube ad primary peritoneal carcinomas across England
Ovarian Cancer Audit Feasibility Pilot Steering Group. Short-term mortality in ovarian, fallopian tube ad primary peritoneal carcinomas across England. NHS Digital, Leeds; 2022. …
Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study).
Jenkinson D, Freeman K, Clements K, Hilton B, Dulson-Cox J, Kearins O, et al.
Abstract:
Introduction The National Health Service (NHS) Breast Screening Programme aims to detect cancer earlier when treatment is …
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.
Maxwell AJ, Hilton B, Clements K, Dodwell D, Dulson-Cox J, Kearins O, et al.
Background and aim
The natural history of ductal carcinoma in situ (DCIS) is poorly understood. The aim of this cohort study was to …
Artificial Intelligence in Drug Design: Opportunities and Challenges
Thomas M, Boardman A, Garcia-Ortegon M, Yang H, de Graaf C, Bender A
Abstract:
Artificial intelligence (AI) has undergone rapid development in recent years and has been successfully applied to real-world problems …
Demographics and survival outcomes in patients with advanced or recurrent endometrial cancer (EC) following platinum-based doublet (PBD) in the English real-world (RW) setting
Knott CS, Heffernan K, Nikitas FS, Shukla U, Starkie-Camejo H. 812P
Abstract:
Background
Patients with advanced/recurrent EC following disease progression on or after a PBD therapy have a poor prognosis. This …
No results found.